Phase I Randomized Safety Study of Twice Daily Dosing of Acidform Vaginal Gel: Candidate Antimicrobial Contraceptive

PLoS ONE

Volumn 7, Issue 10, 2012, Pages

  Keller, Marla J ^a   Carpenter, Colleen A ^a   Lo, Yungtai ^a   Einstein, Mark H ^a   Liu, Congzhou ^b   Fredricks, David N ^b   Herold, Betsy C ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b USA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACIDFORM; AMPHORA; ANTIINFECTIVE AGENT; CARBOPOL 974P; CONTRACEPTIVE AGENT; DEFENSIN 1; DEFENSIN 2; DEFENSIN 3; GAMMA INTERFERON; HYDROXYETHYLCELLULOSE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; LACTOFERRIN; LYSOZYME; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; PLACEBO; RANTES; SECRETORY LEUKOCYTE PROTEINASE INHIBITOR; UNCLASSIFIED DRUG;

ABDOMINAL CRAMP; ADULT; ANTIMICROBIAL ACTIVITY; ARTICLE; CERVICOVAGINAL LAVAGE; CONTROLLED STUDY; DRUG FORMULATION; DRUG SAFETY; ESCHERICHIA COLI; FEMALE; GARDNERELLA VAGINALIS; HUMAN; HUMAN EXPERIMENT; LACTOBACILLUS CRISPATUS; LACTOBACILLUS JENSENII; MUCOSAL IMMUNITY; NONHUMAN; NORMAL HUMAN; PELVIC EXAMINATION; PH; PHASE 1 CLINICAL TRIAL; POLYMERASE CHAIN REACTION; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; SEXUAL BEHAVIOR; SPECIES DIFFERENCE; SYMPTOMATOLOGY; UNITED STATES; VAGINA BLEEDING; VAGINA FLORA; VAGINAL BURNING SENSATION; VAGINAL DRYNESS; VAGINAL GEL; VAGINAL LAVAGE; VAGINAL PRURITUS; VAGINAL SECRETION; VAGINITIS; VULVA DISEASE; VULVA PRURITUS; VULVAR ABRASION; VULVAR ERYTHEMA;

ADOLESCENT; ADULT; ANTI-INFECTIVE AGENTS; BUFFERS; CERVIX UTERI; FEMALE; GYNECOLOGICAL EXAMINATION; HUMANS; HYDROGEN-ION CONCENTRATION; INFLAMMATION MEDIATORS; LACTIC ACID; MEDICATION ADHERENCE; METAGENOME; MIDDLE AGED; SAFETY; SPERMATOCIDAL AGENTS; TIME FACTORS; VAGINA; VAGINAL CREAMS, FOAMS, AND JELLIES; YOUNG ADULT;

EID: 84867300945     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0046901     Document Type: Article

References (40)

1. Heffron R, Donnell D, Rees H, Celum C, Mugo N, et al. (2012) Use of hormonal contraceptives and risk of HIV-1 transmission: a prospective cohort study. The Lancet infectious diseases 12: 19-26.
2. Lavreys L, Baeten JM, Martin HL Jr, Overbaugh J, Mandaliya K, et al. (2004) Hormonal contraception and risk of HIV-1 acquisition: results of a 10-year prospective study. AIDS 18: 695-697.
3. Martin HL Jr, Nyange PM, Richardson BA, Lavreys L, Mandaliya K, et al. (1998) Hormonal contraception, sexually transmitted diseases, and risk of heterosexual transmission of human immunodeficiency virus type 1. The Journal of infectious diseases 178: 1053-1059.
4. Roddy RE, Zekeng L, Ryan KA, Tamoufe U, Tweedy KG, (2002) Effect of nonoxynol-9 gel on urogenital gonorrhea and chlamydial infection: a randomized controlled trial. JAMA: the journal of the American Medical Association 287: 1117-1122.
5. Roddy RE, Zekeng L, Ryan KA, Tamoufe U, Weir SS, et al. (1998) A controlled trial of nonoxynol 9 film to reduce male-to-female transmission of sexually transmitted diseases. The New England journal of medicine 339: 504-510.
6. Van Damme L, Ramjee G, Alary M, Vuylsteke B, Chandeying V, et al. (2002) Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomised controlled trial. Lancet 360: 971-977.
7. Garg S, Anderson RA, Chany CJ, 2nd, Waller DP, Diao XH, et al (2001) Properties of a new acid-buffering bioadhesive vaginal formulation (ACIDFORM). Contraception 64: 67-75.
8. Mayer KH, Peipert J, Fleming T, Fullem A, Moench T, et al. (2001) Safety and tolerability of BufferGel, a novel vaginal microbicide, in women in the United States. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America 32: 476-482.
9. van De Wijgert J, Fullem A, Kelly C, Mehendale S, Rugpao S, et al. (2001) Phase 1 trial of the topical microbicide BufferGel: safety results from four international sites. Journal of acquired immune deficiency syndromes 26: 21-27.
10. Abdool Karim SS, Richardson BA, Ramjee G, Hoffman IF, Chirenje ZM, et al. (2011) Safety and effectiveness of BufferGel and 0.5% PRO2000 gel for the prevention of HIV infection in women. AIDS 25: 957-966.
11. Barnhart KT, Rosenberg MJ, MacKay HT, Blithe DL, Higgins J, et al. (2007) Contraceptive efficacy of a novel spermicidal microbicide used with a diaphragm: a randomized controlled trial. Obstetrics and gynecology 110: 577-586.
12. Tuyama AC, Cheshenko N, Carlucci MJ, Li JH, Goldberg CL, et al. (2006) ACIDFORM inactivates herpes simplex virus and prevents genital herpes in a mouse model: optimal candidate for microbicide combinations. The Journal of infectious diseases 194: 795-803.
13. Pilipenko V, Bourne N, Zanefeld L, Garg S, Waller D, et al. (1999) A new nonoxynol-9 formulation (Acidform) significantly impacts experimental genital tract chlamydial infection in a mouse model. Programs and abstracts of the Conference of the International Society of Sexually Transmitted Diseases; Denver, Colorado, United States of America.
14. Spencer SE, Valentin-Bon IE, Whaley K, Jerse AE, (2004) Inhibition of Neisseria gonorrhoeae genital tract infection by leading-candidate topical microbicides in a mouse model. The Journal of infectious diseases 189: 410-419.
15. Amaral E, Perdigao A, Souza MH, Mauck C, Waller D, et al. (2004) Postcoital testing after the use of a bio-adhesive acid buffering gel (ACIDFORM) and a 2% nonoxynol-9 product. Contraception 70: 492-497.
16. Amaral E, Faundes A, Zaneveld L, Waller D, Garg S, (1999) Study of the vaginal tolerance to Acidform, an acid-buffering, bioadhesive gel. Contraception 60: 361-366.
17. Schwartz JL, Lai JJ, Crenin M, Bradley L, Thomas M, et al. (2006) Fourteen day safety and acceptability study of ACIDFORM gel: a randomized phase I safety study; Cape Town, South Africa.
18. von Mollendorf CE, Van Damme L, Moyes JA, Rees VH, Callahan MM, et al. (2010) Results of a safety and feasibility study of the diaphragm used with ACIDFORM Gel or K-Y Jelly. Contraception 81: 232-239.
19. The Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events, Version 1, December 2004. Available: http://rsc.tech-res.com/safetyandpharmacovigilance/gradingtables.aspx. Accessed 2012 Mar 25.
20. Tien D, Schnaare RL, Kang F, Cohl G, McCormick TJ, et al. (2005) In vitro and in vivo characterization of a potential universal placebo designed for use in vaginal microbicide clinical trials. AIDS research and human retroviruses 21: 845-853.
21. Keller MJ, Madan RP, Torres NM, Fazzari MJ, Cho S, et al. (2011) A randomized trial to assess anti-HIV activity in female genital tract secretions and soluble mucosal immunity following application of 1% tenofovir gel. PloS one 6: e16475.
22. Wallace AR, Teitelbaum A, Wan L, Mulima MG, Guichard L, et al. (2007) Determining the feasibility of utilizing the microbicide applicator compliance assay for use in clinical trials. Contraception 76: 53-56.
23. Austin MN, Rabe LK, Hillier SL, (2009) Limitations of the dye-based method for determining vaginal applicator use in microbicide trials. Sexually transmitted diseases 36: 368-371.
24. Fredricks DN, Fiedler TL, Thomas KK, Mitchell CM, Marrazzo JM, (2009) Changes in vaginal bacterial concentrations with intravaginal metronidazole therapy for bacterial vaginosis as assessed by quantitative PCR. Journal of clinical microbiology 47: 721-726.
25. Khot PD, Ko DL, Hackman RC, Fredricks DN, (2008) Development and optimization of quantitative PCR for the diagnosis of invasive aspergillosis with bronchoalveolar lavage fluid. BMC infectious diseases 8: 73.
26. Fredricks DN, Fiedler TL, Thomas KK, Oakley BB, Marrazzo JM, (2007) Targeted PCR for detection of vaginal bacteria associated with bacterial vaginosis. Journal of clinical microbiology 45: 3270-3276.
27. Rosner B, editor (1999) Fundamentals of Biostatistics. 5th edition ed. Pacific Grove: Duxbury Press.
28. Keller MJ, Guzman E, Hazrati E, Kasowitz A, Cheshenko N, et al. (2007) PRO 2000 elicits a decline in genital tract immune mediators without compromising intrinsic antimicrobial activity. AIDS 21: 467-476.
29. Shrier LA, Bowman FP, Lin M, Crowley-Nowick PA, (2003) Mucosal immunity of the adolescent female genital tract. The Journal of adolescent health: official publication of the Society for Adolescent Medicine 32: 183-186.
30. Usala SJ, Usala FO, Haciski R, Holt JA, Schumacher GF, (1989) IgG and IgA content of vaginal fluid during the menstrual cycle. The Journal of reproductive medicine 34: 292-294.
31. Madan RP, Carpenter C, Fiedler T, Kalyoussef S, McAndrew TC, et al. (2012) Altered biomarkers of mucosal immunity and reduced vaginal lactobacillus concentrations in sexually active female adolescents. PloS one 7: e40415.
32. Kalyoussef S, Nieves E, Dinerman C, Carpenter C, Viswanathan S, et al. (2012) Lactobacillus proteins are associated with the bactericidal activity against E. coli of female genital tract secretions. The Journal of infectious diseases submitted.
33. Eschenbach DA, Patton DL, Hooton TM, Meier AS, Stapleton A, et al. (2001) Effects of vaginal intercourse with and without a condom on vaginal flora and vaginal epithelium. The Journal of infectious diseases 183: 913-918.
34. Ghartey JP, Carpenter C, Gialanella P, Rising C, McAndrew TC, et al. (2012) Association of bactericidal activity of genital tract secretions with Escherichia coli colonization in pregnancy. American journal of obstetrics and gynecology in press.
35. Marchetti M, Trybala E, Superti F, Johansson M, Bergstrom T, (2004) Inhibition of herpes simplex virus infection by lactoferrin is dependent on interference with the virus binding to glycosaminoglycans. Virology 318: 405-413.
36. Fredricks DN, Fiedler TL, Marrazzo JM, (2005) Molecular identification of bacteria associated with bacterial vaginosis. The New England journal of medicine 353: 1899-1911.
37. Ravel J, Gajer P, Abdo Z, Schneider GM, Koenig SS, et al. (2011) Vaginal microbiome of reproductive-age women. Proceedings of the National Academy of Sciences of the United States of America 108 (Suppl 1): 4680-4687.
38. Hogarty K, Kasowitz A, Herold BC, Keller MJ, (2007) Assessment of adherence to product dosing in a pilot microbicide study. Sexually transmitted diseases 34: 1000-1003.
39. Katzen LL, Fernandez-Romero JA, Sarna A, Murugavel KG, Gawarecki D, et al. (2011) Validation of a dye stain assay for vaginally inserted hydroxyethylcellulose-filled microbicide applicators. Sexually transmitted diseases 38: 1050-1055.
40. Moench TR, O'Hanlon DE, Cone RA, (2012) Evaluation of microbicide gel adherence monitoring methods. Sexually transmitted diseases 39: 335-340.